Regulatory Approval & Exclusivity Challenges for Libervant: The company faces risks related to securing full regulatory approval and overcoming market exclusivity periods for key product candidates like Libervant, which could delay or prevent commercialization and significantly impact revenue generation.

Commercialization Success & Market Adoption Risks: Achieving commercial success for approved products like Sympazan and future launches requires effective marketing, sales, and market access, as well as physician and patient adoption, which may not materialize as anticipated due to various factors including competition and reimbursement.

Clinical Trial & Product Development Failure: The company's pipeline products are subject to the inherent risks of clinical development, including the possibility of trial failures, unexpected safety issues, or insufficient efficacy data, which could prevent regulatory approval and lead to significant financial losses.